Analysts Set Abeona Therapeutics Inc. (NASDAQ:ABEO) PT at $20.00

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have received an average rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $20.00.

A number of research analysts have commented on the stock. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st.

Abeona Therapeutics Stock Down 0.6%

Shares of NASDAQ:ABEO opened at $5.26 on Wednesday. The firm has a market capitalization of $285.04 million, a PE ratio of 4.28 and a beta of 1.18. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.54. The firm has a fifty day moving average of $5.17 and a 200 day moving average of $5.45.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Christine Berni Silverstein sold 20,070 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $102,156.30. Following the completion of the sale, the director owned 137,722 shares in the company, valued at approximately $701,004.98. The trade was a 12.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Joseph Walter Vazzano sold 18,666 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total value of $99,489.78. Following the sale, the chief financial officer directly owned 568,560 shares of the company’s stock, valued at approximately $3,030,424.80. This trade represents a 3.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 209,605 shares of company stock valued at $1,101,300. 5.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC bought a new position in shares of Abeona Therapeutics during the fourth quarter valued at about $10,540,000. Boone Capital Management LLC purchased a new position in Abeona Therapeutics during the 2nd quarter valued at about $7,126,000. Tang Capital Management LLC purchased a new position in Abeona Therapeutics during the 4th quarter valued at about $5,270,000. Geode Capital Management LLC raised its position in Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after purchasing an additional 623,243 shares during the last quarter. Finally, Aberdeen Group plc purchased a new stake in Abeona Therapeutics in the 4th quarter worth approximately $3,248,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.